Among patients with relapsed or refractory multiple myeloma (MM) who stop responding to lenalidomide, combination therapy with pomalidomide, daratumumab, and dexamethasone (DPd) may provide clinical benefit, according to research presented at the SOHO 2023 Annual Meeting.

The phase 2 MM-014 trial ( Identifier: NCT01946477) was designed to investigate the clinical benefit of pomalidomide-based regimens among patients with relapsed/refractory MM who exhausted use of lenalidomide in the first or second lines. Cohort B of MM­-014 evaluated DPd, which appeared to show clinical promise in this setting.

At the SOHO 2023 Annual Meeting, researchers presented final overall survival (OS) data from patients enrolled to cohort B of MM-014, with a median follow-up of 41.9 months.

Continue Reading

Overall, 112 patients were enrolled to cohort B. At baseline, the median age was 66.5 years, 67.9% of patients were male, 75.9% of patients were refractory to lenalidomide, and 61.6% of patients had received 1 prior therapy line.

In the intention-to-treat population, the overall response rate was 78.6%; in the lenalidomide-relapsed and -refractory subgroups, the overall response rates were 81.5% and 77.6%, respectively.

Further analysis showed that the median OS was 56.7 months (95% CI: 47.6-not reached). In the lenalidomide-relapsed group, median OS was not reached, compared with 53.6 months in the lenalidomide-refractory group.

The most commonly noted grade 3 or 4 treatment-related adverse events were neutropenia (64.3%), anemia (19.6%), and pneumonia (17.9%).

“Given the high response rates and encouraging safety profile of DPd, a class switch may not be necessary in patients who experience [progressive disease] on or after [lenalidomide],” the authors noted in their poster.

Disclosures: This research was supported by Bristol Myers Squibb. Please see the original reference for a full list of disclosures.


Bahlis NJ, Samaras C, Reece D, et al. Pomalidomide, daratumumab, and dexamethasone after lenalidomide treatment in patients with relapsed or refractory multiple myeloma: final overall survival analysis of the phase 2 MM-014 study. Presented at: the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO); September 6-9, 2023. Abstract MM-371.